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manifestations and laboratory findings, systemic 
sclerosis is classified into 2 types: diffuse 
and limited systemic sclerosis. Cutaneous 
involvement in diffuse systemic sclerosis extend 
up to proximal knees and elbows, face and trunk. 
Raynaud’s phenomenon usually follows cutaneous 
manifestations. Organ involvement such as 
musculoskeletal, kidneys, heart and lungs often 
appear. Signs of limited systemic sclerosis are 
known from the mnemonic CREST syndrome, 
consisting of calcinosis, Raynaud’s phenomenon, 
esophageal dysmotility, sclerodactyly and 
telangiectasia.2 
Ten years survival rate of systemic sclero-
sis patient has increased significantly from 53% 
in 1970s to 67% in 1990s.3 However, this rate is 
lower than SLE patients, which is 93%.4 A previous 
study stated that most frequent cause of death in 
systemic sclerosis patients is related to heart and 
lungs involvement.5 Irreversible organ involvement 
following disease progression may further compli-
cates the disease, hence the long-term prognosis of 
systemic sclerosis depends on organ involvement 
and disease manifestation.
Systemic sclerosis is the third most common 
patients in rheumatology clinic Dr. Hasan Sadikin 
General Hospital, after systemic lupus erythemato-
sus (SLE) and rheumatoid arthritis (RA).6 Most of 
them often delayed referral, diagnosis, and manage-
ment of systemic sclerosis from primary health care 
and district hospital take place. As a consequences, 
patients come to rheumatology clinic Dr. Hasan 
Sadikin General Hospital Bandung in severe con-
dition with multiple organ involvement. Delayed 
referral corresponds with the low education profile 
of health care provider regarding clinical manifes-
tation and laboratory findings of systemic sclerosis. 
As a result, a study about clinical manifestations 
and laboratory findings of systemic sclerosis pa-
tient is needed as an important information to help 
health care providers establish early diagnosis as a 
way to prevent irreversible organ involvement.
Method
This study conducted during September−October 
2016 at rheumatology clinic Dr. Hasan Sadikin 
General Hospital Bandung. Medical records of 
Abstract
Background: Systemic sclerosis is a chronic 
progressive multisystem autoimmune disease in 
connective tissue, characterized by its heterogeneous 
clinical manifestation. The purpose of this study is to 
give information regarding clinical manifestations and 
laboratory findings of systemic sclerosis patients to 
establish diagnosis of disease.
Method: This study was conducted using descriptive 
quantitative design in September−October 2016. Data 
was collected from medical records of patients visiting 
Rheumatology Clinic Dr. Hasan Sadikin General Hospital 
from 1 July 2015−30 June 2016 using total sampling 
method. The collected data were expected to comprise 
patient’s clinical manifestation and laboratory finding.
Result: Most of patients had cutaneous 57 (100.0%) 
and musculoskeletal 40 (70.2%) involvement. Some 
of the disease manifestations were Raynaud’s 
phenomenon 38 (66.7%), fingertip lesion 33 (57.9%), 
stiffness in skin 34 (59.6%), and arthalgia 29 (50.9%). 
Gastrointestinal involvements were present in 29 
(50.9%) patients. Renal involvement were determined 
from urinalysis result showed proteinuria 10 (17.5%) 
and hematuria 8 (14.0%), found in 24 (42.1%) patients, 
while pulmonary and cardiac involvements were found 
in 30 (52.6%) patients, acknowledged from clinical 
symptoms such as dyspnea 12 (21.1%). Identification of 
autoantibodies was found in 12 (21.1%) patients, with 
10 (17.5%) patients had reactive ANA and 3 (3.5%) had 
positive anti-Scl70.
Conclusion: Most of systemic sclerosis patients had 
cutaneous involvement. Renal, pulmonary, and cardiac 
involvement were concluded based on laboratory 
findings.
Keywords: Systemic sclerosis, clinical manifestation, 
laboratory finding
Introduction
Systemic sclerosis (SSc) is a chronic progressive 
multisystem autoimmune disease in connective 
tissue, characterized by its heterogeneous clinical 
manifestation. Pathophysiologic processes that 
occur on this disease are vascular abnormality, 
fibrosis due to collagen deposits and excessive 
extracellular matrix and autoimmunity.1 Based 
on cutaneous involvement patterns, clinical 
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patients was analyzed and presented descriptively using 
a retrospective method. Sample was selected using total 
sampling method. Subjects of this study were patients 
diagnosed with systemic sclerosis who were treated at 
rheumatology clinic Dr. Hasan Sadikin General Hospital 
Bandung during July 1, 2015 to June 20, 2016. After ethical 
clearance letter had been issued, clinical manifestations and 
results of supportive examination that the patient took were 
recorded from their medical records. Afterwards, data were 
grouped based on cutaneous, gastrointestinal, renal, cardiac 
and pulmonary involvement. The exclusion criteria of the 
study was patients who have not been completed data on their 
medical records and patients with overlap syndrome or mixed 
connective tissue disease (MCTD).
Result
Total participants who fulfilled inclusion were 57 patients. 
Table 1 showed characteristic of systemic sclerosis patients 
in rheumatology clinic Dr. Hasan Sadikin General Hospital. 
The table showed that most of systemic sclerosis patients 
was female 56 (98.2%) with age range from 31−40 years 19 
(33,3%).
Table 1. Characteristics of SSc patients at rheumatology clinic Dr. 
Hasan	Sadikin	Bandung	General	Hospital	in	July	2015−June	2016
Characteristics Frequency (n=57) Percentage (%)
Sex
Female
Male
56
1
98.2%
1.8%
Age
<20 years
20-30 years
31-40 years
41-50 years
51-60 years
>60 years
1
9
19
17
5
6
1.8%
15.8%
33.3%
29.8%
8.8%
10.5%
Table 2 showed the distribution of clinical manifestation 
in involved organ on patients with systemic sclerosis at rheu-
matology clinic Dr. Hasan Sadikin General Hospital Bandung. 
The table showed that all 57 subjects are patient with cuta-
neous involvement (100.0%). Raynaud’s phenomenon was 
found in 38 (67.9%) patients.
Table 2. Distribution of clinical manifestations on organs involved 
in SSc patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital	Bandung	in	July	2015−June	2016
Clinical Manifestation Frequency (n=57) Percentage (%)
Skin
Raynaud’s Phenomenon
Fingertip lesion
Telangiectasia
Calsinosis cutis
Sclerodactyly
Hardened skin
0Skin stiffness
Painful skin
Itchy skin
n = 57
38
33
9
21
25
25
34
26
16
100.0%
66.7%
57.9%
15.8%
36.8%
43.9%
43.9%
59.6%
45.6%
28.1%
Clinical Manifestation Frequency (n=57) Percentage (%)
Mask-face
Fish mouth
Salt and pepper appearance
8
22
19
14.0%
38.6%
33.3%
Gastrointestinal
Nausea
Difficulty in swallowing
Epigastric pain
Diarrhea
n = 29
14
13
6
4
50.9%
24.6%
22.8%
10.5%
7.0%
Musculoskeletal
Swelling fingers
Arthalgia
Myalgia
Joint stiffness
Muscle contracture
Knee pain
Back pain
n = 40
14
29
13
10
2
6
4
70.2%
24.6%
50.9%
22.8%
17.5%
3.5%
10.5%
7.0%
Renal n=24 42.1%
Pulmonary and cardiac n=30 52.6%
 
Table 3 showed multiple of organ involvements in system-
ic sclerosis patient. Most patients (40.4%) had combination of 
skin, musculoskeletal, and gastrointestinal organ 
Table 3. Distribution of multiple organ involvements in SSc 
patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital	Bandung	in	July	2015−June	2016
Multiple Organ Involvements Frequency (n=57) Percentage (%)
Skin only 13 22.8%
Skin and musculoskeletal 16 28.1%
Skin and gastrointestinal 5 8.8%
Skin, musculoskeletal, and 
gastrointestinal
23 40.4%
  
Table 4 showed the distribution of constitutional symptoms 
which appeared on systemic sclerosis patients at rheumatology 
clinic Dr. Hasan Sadikin General Hospital. The table showed 
that the most frequent constitutional symptoms experienced 
by patients were easy fatigability 12 (21.1%) and weakness 
11 (19.3%).
Table 4. Distribution of constitutional symptoms in SSc patients 
at rheumatology clinic Dr. Hasan Sadikin General Hospital Band-
ung	in	July	2015−June	2016
Constitutional Symptom Frequency (n=57) Percentage (%)
Easily fatigue 12 21.1%
Weakness 11 19.3%
Hair fall 6 10.5%
Epistaxis 4 7.0%
Weight loss 8 14.0%
Renal, cardiac and pulmonary involvement in patients with 
systemic sclerosis can be assessed from clinical manifestations 
and/or supporting examination. Examinations which usually 
carried out were routine urinalysis, serum creatinine, plain 
chest x-ray, chest CT scan, spirometry and echocardiography. 
Table 5 showed the distribution of clinical manifestations and 
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laboratory findings of systemic sclerosis patients with renal, 
cardiac and pulmonary involvement at Dr. Hasan Sadikin 
General Hospital.
Tabel 5. Distribution of clinical manifestations and laboratory 
findings on renal, cardiac, and pulmonary involvement in SSc 
patients at rheumatology clinic Dr. Hasan Sadikin General 
Hospital	Bandung	in	July	2015−June	2016
Organ Involvement Frequency (n=57) Percentage (%)
Renal Involvement
Clinical manifestation
Dysuria
Oligouria
Laboratory findings
Urinalysis
Proteinuria
Hematuria
Bakteriuria
Increased creatinine serum
n=24
6
2
10
8
3
4
42.1%
10,5%
3,5%
17,5%
14,0%
5,3%
7,0%
Pulmonary and Cardiac Involvement 
Clinical manifestation
Dyspnea
Dyspnea with edema in lower 
extremities
Dyspnea with cough
Cough
Palpitation
Laboratory findings
Plain chest x-ray
Cardiomegaly
Cardiomegaly without pulmonary 
edema
Suspected ILD
Idiopathic pulmonary fibrosis
CT Scan
ILD appearance
Spirometry
Mild restrictive
Moderate restrictive
Echocardiography
Pulmonary hypertension 
Diastolic dysfunction
n=30
12
2
7
5
2
2
5
2
1
3
2
4
2
1
52,6%
21,1%
3,5%
12,3%
8,8%
3,5%
3,5%
8,8%
3,5%
1,8%
5,3%
3,5%
7,0%
3,5%
1,8%
 
Table 6 showed the distribution of autoantibody test result 
on systemic sclerosis patients at Dr. Hasan Sadikin General 
Hospital Bandung. The tests included antinuclear antibody 
(ANA) and anti-Scl70.
Table 6. Distribution of autoantibody test in SSc patients at 
rheumatology clinic Dr. Hasan Sadikin General Hospital Bandung 
in	July	2015−June	2016
Autoantibody Frequency (n=57) Percentage (%)
Autoantibody test
ANA
Reactive
Speckled pattern
Nuclear pattern
Homogenous type
Not-specified
Non-reactive
Anti-Scl70
Positive
n=12
10
2
3
3
2
2
3
21.1%
17.5%
3.5%
5.3%
5.3%
3.5%
3.5%
5.3%
N/A 45 78.9%
Discussion
It was obtained from this study that most patients with 
systemic sclerosis were female 56 (98.2%) with age range 
from 31-40 years 19 (33.3%). This result corresponded with 
previous study conducted by Pagalavan dan Ong in Malaysia, 
where most systemic sclerosis patients were 31−40 years old 
female.7
All systemic sclerosis patients showed cutaneous 
involvement as disease manifestation. This result suited 
to previous study which stated that even though clinical 
manifestations in systemic sclerosis were heterogeneous, 
most patients had cutaneous involvement.8 Systemic 
sclerosis patients which showed clinical manifestation and 
positive laboratory findings on organs without any cutaneous 
involvement were called systemic sclerosis sine scleroderma 
(ssSSc). On a study conducted by Marangoni, et al., in Brazil, 
it was found that among 947 systemic sclerosis patients, there 
were only 79 (8.3%) patients with ssSSc.9
Based on Le Roy vascular hypothesis, dysfunctional blood 
vessel was an initial pathophysiologic process in systemic 
sclerosis marked by Raynaud’s phenomenon.10 The result of 
this study revealed that the most frequent clinical manifestation 
found on skin was Raynaud’s phenomenon (66.7%). This 
result corresponded with a previous study conducted by 
Pagalavan and Ong in Malaysia, where 38 (83.6%) patients 
with systemic sclerosis experienced Raynaud’s phenomenon.7 
Hanitsch in Germany published a higher rate; 1160 (96.7%) 
patients experienced Raynaud’s phenomenon.11
This study revealed that 9 (15.8%) patients experienced 
telangiectasia and 21 (36.8%) patients experienced cutaneous 
calcinosis. This result was different with the study by 
Pagalavan and Ong in Malaysia, where 28 (45.9%) patients 
experienced telangiectasia and 7 (11.5%) patients experienced 
calcinosis cutis.7 The result might be affected by the type of 
systemic sclerosis experienced by patients, calcinosis cutis 
was more frequently found in limited systemic sclerosis.12
Musculoskeletal involvement as the main cause of 
disability was frequently found on systemic sclerosis.13  From 
the study result, it was revealed that 40 (70.2%) systemic 
sclerosis patients had a musculoskeletal involvement. The 
most frequently found manifestation was arthalgia 29 (50.9 
%). This result was suitable with the previous literature 
which stated that the most common clinical manifestation 
on musculoskeletal involvement was arthalgia.14 This result 
corresponded with the study by Pagalavan and Ong in Malaysia 
which reported that arthalgia/arthritis were frequently found 
(49.2%).7
There were 29 (50.9%) systemic sclerosis patients in 
this study with gastrointestinal involvement. The most 
manifestation which frequently found was difficulty in 
swallowing 13 (22.8%). This result corresponded with 
previous study which stated that gastroesophageal reflux 
and dysphagia were the frequent manifestations of systemic 
sclerosis on patients.15 The other common complaint were 
nausea 14 (22.8%). These gastrointestinal manifestations 
were one factor which might cause malnutrition on systemic 
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sclerosis patients. Baron, et al reported 18% patients were at 
risk for malnutrition.16
On this study, the most frequent constitutional symptoms 
reported by systemic sclerosis patients were fatigue (21.1%) 
and weakness (19.3%). This result suited to previous study 
by Sandusky, et al., in USA which stated that 76% subjects 
experienced fatigue, while 61% of those patients stated that 
this was one of the most physically and socially disturbing 
symptoms.17
Renal involvement on systemic sclerosis patients can 
be assessed from clinical features or from supporting 
examination. On this study, there were 24 (42.1%) patients 
with renal involvement; 8 (14.0%) patients with clinical 
symptoms such as dysuria (10.5%) and oliguria (3.5%), while 
the rest of them had abnormal supporting examination test 
result. The supporting examinations conducted were routine 
urinalysis and serum creatinine level. Abnormalities found on 
patients from those test were proteinuria (17.5%), hematuria 
(14.0%) and bacteriuria (5.3%). Albuminuria could be used as 
vasculopathy marker, which was one of the pathophysiologic 
processes on systemic sclerosis.18 On this study, increasing 
creatinine serum level was found on 4 (7.0%) patients. The 
increasing creatinine serum level did not completely describe 
a renal dysfunction, since renal dysfunction could also occur 
on patients with normal creatinine serum level.18
There were 30 (52.6%) patients on this study showed 
cardiac and pulmonary involvement marked by clinical 
manifestations and supporting examination. On this study, 
there were 12 (21.1%) patients with dyspnea, 2 (3.5%) 
patients with dyspnea and edema on extremities and 7 
(12.3%) patients with dyspnea and cough. Meanwhile, a study 
by Hanitsch in Germany reported 390 (32.5%) patients had 
dyspnea.11 Patients with dyspnea needed further observation 
and screening for pulmonary hypertension. The most frequent 
pulmonary manifestations and the main cause of death on 
60% systemic sclerosis patients were interstitial lung disease 
(ILD) and pulmonary hypertension.19 From plain chest x-ray 
and chest CT scan, respectively there were 2 (3.5%) and 3 
(5.3%) patients with interstitial lung disease, while from 
echocardiography there were 2 (3.5%) patients with pulmonary 
hypertension. Systolic and diastolic dysfunction are early 
signs of heart problems on patients with systemic sclerosis.20 
On this study, there were 1 (1.8%) patients presented with 
diastolic dysfunction from echocardiography.
One of the pathophysiologic process occur on systemic 
sclerosis is the synthesis of autoantibody. The number and 
level of this autoantibody fluctuates depending on the disease 
activity, hence it could be used as diagnostic markers and 
determine prognosis of systemic sclerosis.2 There were 10 
(17.5%) patients on this study had positive ANA (antinuclear 
antibody) test result while 3 (5.3%) patients with positive 
anti-Scl70. This result was different from Pagalavan and Ong 
in Malaysia who stated that there were 51 (83.6%) patients 
with positive ANA and 21 (34.4%) patients with positive 
anti-Scl70 test result. This difference because not all patients 
who were treated at rheumatology clinic Dr. Hasan Sadikin 
General Hospital had autoantibody tests.7
Conclusion
From 57 sample, it could be concluded that most systemic 
sclerosis patients had cutaneous involvement, renal, 
pulmonary, and cardiac involvement based on laboratory 
findings.
This study was a retrospective study that evaluated 
history taking and supporting examination test result on 
medical records. Most of the medical records had not been on 
computerized system, hence there could still be a possibility 
that there were mistakes in interpreting the writings on the 
medical records. On the other hand, not all patients took 
autoantibody test hence their records were not reported.
Recommendation from this study is demographic data on 
medical records could be completed. The medical records 
should also comprise the recordings of all examination the 
patient took to help clinician establish the diagnosis of the 
patient.
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